Literature DB >> 25109886

Impact of influenza season and environmental factors on the clinical presentation and outcome of invasive pneumococcal disease.

J Burgos1, M N Larrosa2, A Martinez3, J Belmonte4,5, J González-López2, J Rello6,7, T Pumarola2, A Pahissa8, V Falco8.   

Abstract

Influenza and meteorological factors have been associated with increases in the incidence of invasive pneumococcal disease (IPD). However, scant data regarding the impact of influenza and the environment on the clinical presentation of IPD are available. An observational study of all adults hospitalized with IPD was performed between 1996 and 2012 in our hospital. The incidence of IPD correlated with the incidence rates of influenza and with environmental data. A negative binominal regression was used to assess the relationship between these factors. Clinical presentation of IPD during the influenza and non-influenza periods was compared. During the study, 1,150 episodes of IPD were diagnosed. After adjusting for confounding variables, factors correlating with the rates of IPD were the incidence of influenza infection (IRR 1.229, 95% CI 1.025-1.472) and the average ambient temperature (IRR 0.921, 95% CI 0.88-0.964). Patients with IPD during the influenza period had a worse respiratory status. A greater proportion of patients had respiratory failure (45.6% vs 52%, p = 0.032) and higher requirements for ICU admission (19.3% vs 24.7%, p = 0.018) and mechanical ventilation (11% vs 15.1%, p = 0.038). When we stratified by invasiveness of pneumococcal serotypes and the presence of comorbid conditions, the increase in the severity of clinical presentation was focused on healthy adults with IPD caused by nonhighly invasive serotypes. Beyond the increase in the burden of IPD associated with influenza, a more severe clinical pattern of pneumococcal disease was observed in the influenza period. This effect varied according to pneumococcal serotype, host comorbidities, and age.

Entities:  

Mesh:

Year:  2014        PMID: 25109886     DOI: 10.1007/s10096-014-2221-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  27 in total

1.  Unveiling the burden of influenza-associated pneumococcal pneumonia.

Authors:  Carlos G Grijalva; Marie R Griffin
Journal:  J Infect Dis       Date:  2011-12-07       Impact factor: 5.226

2.  Pneumococcal pneumonia in preschool children: viral coinfection does not worsen clinical outcome.

Authors:  Javier Alvarez-Coca Gonzalez; Jorge Martinez Perez; David Tarrago Asensio; Inmaculada Casas Flecha; Almudena Alonso Ojembarrena; Giovanni Fedele
Journal:  Pediatr Infect Dis J       Date:  2011-02       Impact factor: 2.129

3.  Daily periodicity of susceptibility of mice to pneumococcal infection.

Authors:  R D Feigin; V H San Joaquin; M W Haymond; R G Wyatt
Journal:  Nature       Date:  1969-10-25       Impact factor: 49.962

Review 4.  Insights into the interaction between influenza virus and pneumococcus.

Authors:  Jonathan A McCullers
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

5.  Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States.

Authors:  Nicholas D Walter; Thomas H Taylor; David K Shay; William W Thompson; Lynnette Brammer; Scott F Dowell; Matthew R Moore
Journal:  Clin Infect Dis       Date:  2010-01-15       Impact factor: 9.079

6.  Viral coinfections in children with invasive pneumococcal disease.

Authors:  Benyachalee Techasaensiri; Chonnamet Techasaensiri; Asuncion Mejías; George H McCracken; Octavio Ramilo
Journal:  Pediatr Infect Dis J       Date:  2010-06       Impact factor: 2.129

7.  Seasonal invasive pneumococcal disease in children: role of preceding respiratory viral infection.

Authors:  Krow Ampofo; Jeffrey Bender; Xiaoming Sheng; Kent Korgenski; Judy Daly; Andrew T Pavia; Carrie L Byington
Journal:  Pediatrics       Date:  2008-08       Impact factor: 7.124

8.  Association of respiratory virus activity and environmental factors with the incidence of invasive pneumococcal disease.

Authors:  David R Murdoch; Lance C Jennings
Journal:  J Infect       Date:  2008-11-29       Impact factor: 6.072

9.  Pneumococcal disease seasonality: incidence, severity and the role of influenza activity.

Authors:  Daniel M Weinberger; Zitta B Harboe; Cécile Viboud; Tyra G Krause; Mark Miller; Kåre Mølbak; Helle B Konradsen
Journal:  Eur Respir J       Date:  2013-09-13       Impact factor: 16.671

10.  Lethal synergism of 2009 pandemic H1N1 influenza virus and Streptococcus pneumoniae coinfection is associated with loss of murine lung repair responses.

Authors:  John C Kash; Kathie-Anne Walters; A Sally Davis; Aline Sandouk; Louis M Schwartzman; Brett W Jagger; Daniel S Chertow; Qi Li; Rolf E Kuestner; Adrian Ozinsky; Jeffery K Taubenberger
Journal:  mBio       Date:  2011-09-20       Impact factor: 7.867

View more
  4 in total

1.  HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine (PCV).

Authors:  Susan Meiring; Cheryl Cohen; Vanessa Quan; Linda de Gouveia; Charles Feldman; Alan Karstaedt; Keith P Klugman; Shabir A Madhi; Helene Rabie; Charlotte Sriruttan; Anne von Gottberg
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

Review 2.  Postviral Complications: Bacterial Pneumonia.

Authors:  Jason E Prasso; Jane C Deng
Journal:  Clin Chest Med       Date:  2016-12-13       Impact factor: 2.878

3.  Association of seasonal viral acute respiratory infection with pneumococcal disease: a systematic review of population-based studies.

Authors:  You Li; Meagan E Peterson; Harry Campbell; Harish Nair
Journal:  BMJ Open       Date:  2018-04-21       Impact factor: 2.692

Review 4.  Personalized medicine in severe influenza.

Authors:  F Valenzuela-Sánchez; B Valenzuela-Méndez; J F Rodríguez-Gutiérrez; J Rello
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-03-02       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.